Loading...

Coherus BioSciences

Nasdaq:CHRS
Snowflake Description

High growth potential with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CHRS
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Coherus BioSciences has significant price volatility in the past 3 months.
CHRS Share Price and Events
7 Day Returns
8.1%
NasdaqGM:CHRS
2.8%
US Biotechs
0.1%
US Market
1 Year Returns
10.9%
NasdaqGM:CHRS
-5.6%
US Biotechs
1.2%
US Market
CHRS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Coherus BioSciences (CHRS) 8.1% 1.6% 24.9% 10.9% 20.8% -
US Biotechs 2.8% 1.7% -6% -5.6% 14.4% 9.6%
US Market 0.1% 0.6% 0.9% 1.2% 36.7% 37.9%
1 Year Return vs Industry and Market
  • CHRS outperformed the Biotechs industry which returned -5.6% over the past year.
  • CHRS outperformed the Market in United States of America which returned 1.2% over the past year.
Price Volatility
CHRS
Industry
5yr Volatility vs Market

CHRS Value

 Is Coherus BioSciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Coherus BioSciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Coherus BioSciences.

NasdaqGM:CHRS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:CHRS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.323 (1 + (1- 21%) (13.8%))
1.313
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.313 * 5.96%)
10.55%

Discounted Cash Flow Calculation for NasdaqGM:CHRS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Coherus BioSciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:CHRS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.55%)
2019 -62.85 Analyst x3 -56.85
2020 -32.75 Analyst x2 -26.80
2021 49.80 Analyst x2 36.86
2022 110.30 Analyst x1 73.84
2023 139.21 Analyst x2 84.29
2024 162.95 Est @ 17.05% 89.25
2025 183.73 Est @ 12.75% 91.02
2026 201.64 Est @ 9.75% 90.36
2027 217.05 Est @ 7.64% 87.98
2028 230.44 Est @ 6.17% 84.49
Present value of next 10 years cash flows $554.43
NasdaqGM:CHRS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $230.44 × (1 + 2.73%) ÷ (10.55% – 2.73%)
$3,025.51
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $3,025.51 ÷ (1 + 10.55%)10
$1,109.26
NasdaqGM:CHRS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $554.43 + $1,109.26
$1,663.69
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,663.69 / 69.37
$23.98
NasdaqGM:CHRS Discount to Share Price
Calculation Result
Value per share (USD) From above. $23.98
Current discount Discount to share price of $19.36
= -1 x ($19.36 - $23.98) / $23.98
19.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Coherus BioSciences is available for.
Intrinsic value
19%
Share price is $19.36 vs Future cash flow value of $23.98
Current Discount Checks
For Coherus BioSciences to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Coherus BioSciences's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Coherus BioSciences's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Coherus BioSciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Coherus BioSciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CHRS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.75
NasdaqGM:CHRS Share Price ** NasdaqGM (2019-06-18) in USD $19.36
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.39x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Coherus BioSciences.

NasdaqGM:CHRS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CHRS Share Price ÷ EPS (both in USD)

= 19.36 ÷ -2.75

-7.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Coherus BioSciences is loss making, we can't compare its value to the US Biotechs industry average.
  • Coherus BioSciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Coherus BioSciences's expected growth come at a high price?
Raw Data
NasdaqGM:CHRS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.04x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
69.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.11x
United States of America Market PEG Ratio Median Figure of 2,126 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Coherus BioSciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Coherus BioSciences's assets?
Raw Data
NasdaqGM:CHRS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-0.56
NasdaqGM:CHRS Share Price * NasdaqGM (2019-06-18) in USD $19.36
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 3.03x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
NasdaqGM:CHRS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CHRS Share Price ÷ Book Value per Share (both in USD)

= 19.36 ÷ -0.56

-34.85x

* Primary Listing of Coherus BioSciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Coherus BioSciences has negative assets, we can't compare the value of its assets to the US Biotechs industry average.
X
Value checks
We assess Coherus BioSciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Coherus BioSciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CHRS Future Performance

 How is Coherus BioSciences expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
69.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Coherus BioSciences expected to grow at an attractive rate?
  • Coherus BioSciences's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Coherus BioSciences's earnings growth is expected to exceed the United States of America market average.
  • Coherus BioSciences's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CHRS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CHRS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 69.5%
NasdaqGM:CHRS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 29.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CHRS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CHRS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 504 155 133 3
2022-12-31 396 37 57 3
2021-12-31 323 12 39 5
2020-12-31 257 -12 -6 5
2019-12-31 177 -58 -69 4
NasdaqGM:CHRS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 37 -183 -185
2018-12-31 -159 -209
2018-09-30 0 -142 -196
2018-06-30 0 -141 -196
2018-03-31 1 -161 -208
2017-12-31 2 -200 -238
2017-09-30 2 -257 -265
2017-06-30 165 -278 -122
2017-03-31 178 -250 -137
2016-12-31 190 -253 -127
2016-09-30 199 -160 -104
2016-06-30 44 -158 -259

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Coherus BioSciences's earnings are expected to grow significantly at over 20% yearly.
  • Coherus BioSciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CHRS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Coherus BioSciences Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CHRS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.78 1.78 1.78 1.00
2022-12-31 0.77 0.77 0.77 1.00
2021-12-31 0.55 0.78 0.31 2.00
2020-12-31 -0.08 -0.02 -0.17 3.00
2019-12-31 -1.00 -0.95 -1.04 2.00
NasdaqGM:CHRS Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.75
2018-12-31 -3.22
2018-09-30 -3.23
2018-06-30 -3.31
2018-03-31 -3.71
2017-12-31 -4.48
2017-09-30 -5.34
2017-06-30 -2.60
2017-03-31 -3.09
2016-12-31 -3.04
2016-09-30 -2.56
2016-06-30 -6.59

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Coherus BioSciences will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Coherus BioSciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Coherus BioSciences has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CHRS Past Performance

  How has Coherus BioSciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Coherus BioSciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Coherus BioSciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Coherus BioSciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Coherus BioSciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Coherus BioSciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Coherus BioSciences Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CHRS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 37.10 -185.05 110.28
2018-12-31 -209.34 94.18
2018-09-30 0.00 -195.81 75.32 0.30
2018-06-30 0.00 -195.99 63.94 0.30
2018-03-31 1.40 -207.69 66.78
2017-12-31 1.56 -238.17 69.00
2017-09-30 2.40 -265.02 69.32
2017-06-30 165.24 -122.10 68.98
2017-03-31 177.91 -136.73 59.00
2016-12-31 190.11 -127.34 51.60
2016-09-30 199.46 -103.81 47.28
2016-06-30 43.79 -259.08 43.80
2016-03-31 36.59 -247.92 41.35
2015-12-31 30.04 -223.26 36.05
2015-09-30 26.34 -200.00 29.93 19.34
2015-06-30 35.22 -136.54 23.74 19.34
2015-03-31 33.32 -102.69 18.90 19.34
2014-12-31 31.11 -87.13 16.23
2014-09-30 25.85 -72.59 13.88 7.71
2014-06-30 10.30 -86.19 12.25 7.71
2014-03-31 5.84 -69.94 9.60 5.75
2013-12-31 2.75 -53.64 7.47 7.71
2012-12-31 1.90 -33.02 5.53 4.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Coherus BioSciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Coherus BioSciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Coherus BioSciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Coherus BioSciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Coherus BioSciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CHRS Health

 How is Coherus BioSciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Coherus BioSciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Coherus BioSciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Coherus BioSciences's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Coherus BioSciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Coherus BioSciences has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Coherus BioSciences Company Filings, last reported 2 months ago.

NasdaqGM:CHRS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 -38.52 185.30 96.43
2018-12-31 -38.59 103.09 72.36
2018-09-30 12.39 102.71 117.17
2018-06-30 61.83 102.33 159.82
2018-03-31 -3.09 101.97 95.16
2017-12-31 30.54 101.61 126.91
2017-09-30 54.91 101.26 150.05
2017-06-30 30.86 100.92 118.33
2017-03-31 76.96 100.58 174.82
2016-12-31 19.35 100.26 124.95
2016-09-30 31.72 99.94 159.68
2016-06-30 -61.95 99.63 220.92
2016-03-31 -66.88 99.32 179.56
2015-12-31 -6.93 0.00 158.23
2015-09-30 40.04 0.00 153.69
2015-06-30 96.36 0.00 206.09
2015-03-31 37.99 0.00 115.14
2014-12-31 66.76 0.00 150.39
2014-09-30 9.18 0.00 100.88
2014-06-30 17.17 0.00 109.87
2014-03-31 -60.54 6.71 56.32
2013-12-31 -42.38 4.20 39.55
2012-12-31 9.19 0.00 14.55
  • Coherus BioSciences has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Coherus BioSciences's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Coherus BioSciences has less than a year of cash runway based on current free cash flow.
  • Coherus BioSciences has less than a year of cash runway if free cash flow continues to reduce at historical rates of -6.4% each year.
X
Financial health checks
We assess Coherus BioSciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Coherus BioSciences has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CHRS Dividends

 What is Coherus BioSciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Coherus BioSciences dividends. Estimated to be 0% next year.
If you bought $2,000 of Coherus BioSciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Coherus BioSciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Coherus BioSciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CHRS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CHRS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Coherus BioSciences has not reported any payouts.
  • Unable to verify if Coherus BioSciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Coherus BioSciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Coherus BioSciences has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Coherus BioSciences's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Coherus BioSciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Coherus BioSciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Coherus BioSciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CHRS Management

 What is the CEO of Coherus BioSciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Denny Lanfear
COMPENSATION $3,919,780
AGE 63
TENURE AS CEO 8.8 years
CEO Bio

Mr. Dennis M. Lanfear, also known as Denny, has been the Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Capital Advisors, LLC. He focuses on investments in therapeutic product and device companies. Mr. Lanfear founded InteKrin Therapeutics, Inc. in 2005 and has also been its Chairman of the Board since 2010. He serves as Acting President of InteKrin Therapeutics, Inc. He was President and Chief Executive Officer at InteKrin Therapeutics, Inc. from 2005 to May 2010. Mr. Lanfear was the Founder and Chief Executive Officer at Saronyx, Inc. He served as Strategic Consultant for Insmed Incorporated since October 25, 2006 until December 2007. He was a Corporate Officer and Vice President at Amgen. At Amgen, he began in 1986 as a founder of the Process Development Department. Under his ten-year leadership this group became the preeminent PD organization in biopharma and an area of key strategic advantage for the company. Mr. Lanfear also had senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins, directing efforts from preclinical to Phase III. He reviewed and wrote sections of more than 20 INDs and several BLAs. Mr. Lanfear also managed corporate partner relationships including those with SKB from 1986 to 1990 and Regeneron Pharmaceuticals from 1991 to 1999, where he had direct budgetary responsibility for the $135 million development partnership. In 1997 he was named Vice President of Market Development, where he defined long term competitive and reimbursement strategies for EpogenTM. Prior to Amgen, Mr. Lanfear was at Baxter International where he designed kilogram scale computerized protein purification systems. Mr. Lanfear served as a Director of Insmed Incorporated since December 2007. He served as a Director of BioGenerics, Inc., Anthera Pharmaceuticals Inc. Mr. Lanfear holds B.S. degrees in Chemical Engineering and Biochemistry from Michigan State University and an M.B.A. from the Anderson School of Management at the University of California, Los Angeles.

CEO Compensation
  • Denny's compensation has increased whilst company is loss making.
  • Denny's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Coherus BioSciences management team in years:

4.8
Average Tenure
60
Average Age
  • The tenure for the Coherus BioSciences management team is about average.
Management Team

Denny Lanfear

TITLE
Chairman
COMPENSATION
$4M
AGE
63
TENURE
8.8 yrs

Jean-Frédéric Viret

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
52
TENURE
4.8 yrs

Vince Anicetti

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
63
TENURE
1.1 yrs

Vladimir Vexler

TITLE
Chief Scientific Officer
COMPENSATION
$1M
AGE
60
TENURE
0.6 yrs

V. Lawlis

TITLE
Science Director
COMPENSATION
$212K
AGE
66

Peter Watler

TITLE
Chief Technical Officer
COMPENSATION
$972K
AGE
56
TENURE
5 yrs

David Arrington

TITLE
Vice President of Investor Relations & Corporate Affairs

Matt Hooper

TITLE
Executive VP & General Counsel
AGE
60
TENURE
5.8 yrs

Erik Wiberg

TITLE
Executive Vice President of Corporate Development
TENURE
2.3 yrs

James Hassard

TITLE
Senior Vice President of Marketing & Market Access
Board of Directors Tenure

Average tenure and age of the Coherus BioSciences board of directors in years:

5.2
Average Tenure
62
Average Age
  • The tenure for the Coherus BioSciences board of directors is about average.
Board of Directors

Alan Herman

TITLE
Chairman Emeritus & Member of Advisory Board
COMPENSATION
$1M
AGE
70
TENURE
0.6 yrs

Denny Lanfear

TITLE
Chairman
COMPENSATION
$4M
AGE
63
TENURE
8.8 yrs

V. Lawlis

TITLE
Science Director
COMPENSATION
$212K
AGE
66
TENURE
6.6 yrs

Mats Wahlström

TITLE
Lead Independent Director
COMPENSATION
$230K
AGE
64

Mary Szela

TITLE
Director
COMPENSATION
$187K
AGE
55
TENURE
4.9 yrs

Jim Daly

TITLE
Executive Chairman of Commercial Advisory Committee
AGE
56
TENURE
3.3 yrs

Barbara Finck

TITLE
Member of Scientific Advisory Board
COMPENSATION
$2M
AGE
71

Christos Richards

TITLE
Director
COMPENSATION
$175K
AGE
61
TENURE
8.3 yrs

Ali Satvat

TITLE
Director
COMPENSATION
$185K
AGE
41
TENURE
5.1 yrs

Jim Healy

TITLE
Director
COMPENSATION
$200K
AGE
53
TENURE
5.3 yrs
Who owns this company?
Recent Insider Trading
  • Coherus BioSciences insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
01. Jun 19 Sell Dennis Lanfear Individual 30. May 19 30. May 19 -32,398 $19.49 $-631,282
22. Mar 19 Sell Jean-Frédéric Viret Individual 20. Mar 19 20. Mar 19 -3,000 $14.92 $-44,762
X
Management checks
We assess Coherus BioSciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Coherus BioSciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CHRS News

Simply Wall St News

Update: Coherus BioSciences (NASDAQ:CHRS) Stock Gained 24% In The Last Year

See our latest analysis for Coherus BioSciences Because Coherus BioSciences is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … Coherus BioSciences grew its revenue by 2559% last year. … So quite frankly it could be a good time to investigate Coherus BioSciences in some detail.

Simply Wall St -

When Will Coherus BioSciences, Inc. (NASDAQ:CHRS) Turn A Profit?

Coherus BioSciences, Inc.'s (NASDAQ:CHRS):. … Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. … As path to profitability is the topic on CHRS’s investors mind, I’ve decided to gauge market sentiment.

Simply Wall St -

Is Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Pay Fair?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Denny Lanfear's Compensation Compare With Similar Sized Companies. … is worth US$1.0b, and total annual CEO compensation is US$2.7m.

Simply Wall St -

Intrinsic Calculation For Coherus BioSciences, Inc. (NASDAQ:CHRS) Shows Investors Are Overpaying

Does the January share price for Coherus BioSciences, Inc. … by estimating the company's future cash flows and discounting them to their present value. … discounted cash flows (DCF).

Simply Wall St -

Loss-Making Coherus BioSciences Inc (NASDAQ:CHRS) Expected To Breakeven

Coherus BioSciences Inc's (NASDAQ:CHRS):. … The US$748m market-cap posted a loss in its most recent financial year of -US$238.2m and a latest trailing-twelve-month loss of -US$195.8m shrinking the gap between loss and breakeven? … Check out our latest analysis for Coherus BioSciences

Simply Wall St -

Should You Worry About Coherus BioSciences Inc's (NASDAQ:CHRS) CEO Pay Check?

How Does Denny Lanfear's Compensation Compare With Similar Sized Companies. … According to our data, Coherus BioSciences Inc has a market capitalization of US$820m, and pays its CEO total annual compensation worth US$3m. … It would therefore appear that Coherus BioSciences Inc pays Denny Lanfear more than the median CEO remuneration at companies of a similar size, in the same market

Simply Wall St -

Analysts Expect Breakeven For Coherus BioSciences Inc (NASDAQ:CHRS)

The US$978.32m market-cap company’s loss lessens since it announced a -US$238.17m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$207.69m, as it approaches breakeven. … Many investors are wondering the rate at which CHRS will turn a profit, with the big question being “when will the company breakeven?” … I’ve put together a brief outline of industry analyst expectations for CHRS, its year of breakeven and its implied growth rate

Simply Wall St -

When Will Coherus Biosciences Inc (NASDAQ:CHRS) Become Profitable?

See our latest analysis for Coherus Biosciences Expectation from analysts is CHRS is on the verge of breakeven. … Working backwards from analyst estimates, it turns out that they expect the company to grow 53.41% year-on-year, on average, which is extremely buoyant. … For a more comprehensive look at CHRS, take a look at CHRS’s company page on Simply Wall St.

Simply Wall St -

Why Coherus Biosciences Inc (CHRS) Could Be A Buy

Coherus Biosciences Inc (NASDAQ:CHRS), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. … Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. … If you are no longer interested in Coherus Biosciences, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

Simply Wall St -

CHRS Company Info

Description

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body’s ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Details
Name: Coherus BioSciences, Inc.
CHRS
Exchange: NasdaqGM
Founded: 2010
$1,343,012,047
69,370,457
Website: http://www.coherus.com
Address: Coherus BioSciences, Inc.
333 Twin Dolphin Drive,
Suite 600,
Redwood City,
California, 94065,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CHRS Common Stock Nasdaq Global Market US USD 06. Nov 2014
DB 8C5 Common Stock Deutsche Boerse AG DE EUR 06. Nov 2014
Number of employees
Current staff
Staff numbers
243
Coherus BioSciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/19 00:46
End of day share price update: 2019/06/18 00:00
Last estimates confirmation: 2019/06/10
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.